Functional outcomes of robot-assisted radical prostatectomy in patients eligible for active surveillance

[1] Bill-Axelson A(2008)Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial J Natl Cancer Inst 100 1144-1154

[2] Holmberg L(2011)Managing localized prostate cancer by radical prostatectomy or watchful waiting: cost analysis of a randomized trial (SPCG-4) Scand J Urol Nephrol 45 177-183

[3] Filén F(2012)Radical prostatectomy versus observation for localized prostate cancer N Engl J Med 367 203-213

[4] Andersson S-O(2014)Active surveillance and surgery in localized prostate cancer Minerva Urol E Nefrol Ital J Urol Nephrol 66 175-187

[5] Andrén O(1998)Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 969-974

[6] Lyth J(2010)The Epstein criteria predict for organ-confined but not insignificant disease and a high likelihood of cure at radical prostatectomy Eur Urol 58 90-95

[7] Wilt TJ(2016)Active surveillance for intermediate risk prostate cancer: survival outcomes in the Sunnybrook experience J Urol 196 1651-1658

[8] Brawer MK(2013)Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS) BJU Int 111 53-59

[9] Jones KM(2014)Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer J Urol 191 350-357

[10] Kwon O(2016)Oncological and functional outcomes 1 year after radical prostatectomy for very-low-risk prostate cancer: results from the prospective LAPPRO trial BJU Int 118 205-212

[1] Bill-Axelson A(2008)Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial J Natl Cancer Inst 100 1144-1154

[2] Holmberg L(2011)Managing localized prostate cancer by radical prostatectomy or watchful waiting: cost analysis of a randomized trial (SPCG-4) Scand J Urol Nephrol 45 177-183

[3] Filén F(2012)Radical prostatectomy versus observation for localized prostate cancer N Engl J Med 367 203-213

[4] Andersson S-O(2014)Active surveillance and surgery in localized prostate cancer Minerva Urol E Nefrol Ital J Urol Nephrol 66 175-187

[5] Andrén O(1998)Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 969-974

[6] Lyth J(2010)The Epstein criteria predict for organ-confined but not insignificant disease and a high likelihood of cure at radical prostatectomy Eur Urol 58 90-95

[7] Wilt TJ(2016)Active surveillance for intermediate risk prostate cancer: survival outcomes in the Sunnybrook experience J Urol 196 1651-1658

[8] Brawer MK(2013)Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS) BJU Int 111 53-59

[9] Jones KM(2014)Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer J Urol 191 350-357

[10] Kwon O(2016)Oncological and functional outcomes 1 year after radical prostatectomy for very-low-risk prostate cancer: results from the prospective LAPPRO trial BJU Int 118 205-212